Therapeutic Development

Sobi to Acquire Arthrosi in Up to $1.5 Billion Deal to Bolster Gout Portfolio

The debt-funded purchase adds late-stage URAT1 inhibitor pozdeutinurad with 2026 Phase 3 results expected to guide filings.